HomeCompareREMYF vs MRK

REMYF vs MRK: Dividend Comparison 2026

REMYF yields 4.24% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $36.4K in total portfolio value
10 years
REMYF
REMYF
● Live price
4.24%
Share price
$41.25
Annual div
$1.75
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$0.43
Full REMYF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — REMYF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREMYFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REMYF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REMYF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REMYF
Annual income on $10K today (after 15% tax)
$360.81/yr
After 10yr DRIP, annual income (after tax)
$0.37/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,328.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REMYF + MRK for your $10,000?

REMYF: 50%MRK: 50%
100% MRK50/50100% REMYF
Portfolio after 10yr
$38.6K
Annual income
$4,899.29/yr
Blended yield
12.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

REMYF
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
2.3
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REMYF buys
0
MRK buys
0
No recent congressional trades found for REMYF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREMYFMRK
Forward yield4.24%2.76%
Annual dividend / share$1.75$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7%
Portfolio after 10y$20.4K$56.8K
Annual income after 10y$0.43$9,798.13
Total dividends collected$430.00$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: REMYF vs MRK ($10,000, DRIP)

YearREMYF PortfolioREMYF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,912$212.24$11,206$366.19$294.00MRK
2$11,784$108.23$12,650$502.35$866.00MRK
3$12,664$54.61$14,407$694.19$1.7KMRK
4$13,578$27.43$16,585$967.82$3.0KMRK
5$14,542$13.74$19,342$1,363.89$4.8KMRK
6$15,567$6.88$22,913$1,947.19$7.3KMRK
7$16,660$3.44$27,662$2,823.89$11.0KMRK
8$17,828$1.72$34,159$4,173.35$16.3KMRK
9$19,077$0.86$43,337$6,308.80$24.3KMRK
10$20,412$0.43$56,776$9,798.13$36.4KMRK

REMYF vs MRK: Complete Analysis 2026

REMYFStock

Rémy Cointreau SA, together with its subsidiaries, engages in the production, sale, and distribution of liqueurs and spirits. The company operates through Rémy Martin, Liqueurs & Spirits, and Partner Brands segments. It offers liqueurs, brandy, gin, single malt whisky, rum, wine, and champagne primarily under the Cointreau, Metaxa, St-Rémy, Mount Gay, Bruichladdich, Port Charlotte, Octomore, The Botanist, Westland, LOUIS XIII, and Domaine des Hautes Glaces brands. The operates in Europe, the Middle East, Africa, the Americas, Asia, Australia, and New Zealand. Rémy Cointreau SA was founded in 1724 and is headquartered in Cognac, France.

Full REMYF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this REMYF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REMYF vs SCHDREMYF vs JEPIREMYF vs OREMYF vs KOREMYF vs MAINREMYF vs JNJREMYF vs ABBVREMYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.